Stay in the know
We’ll send you the latest insights and briefings tailored to your needs
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
8 มิถุนายน 2026
Herbert Smith Freehills Kramer advised BNP Paribas Asset Management on launch of a new evergreen Luxembourg RAIF offering Scottish Widows customers access to private market
Herbert Smith Freehills Kramer has advised BNP Paribas Asset Management, a leading global asset manager, on the establishment and launch of an open-ended …
8 มิถุนายน 2026
Herbert Smith Freehills Kramer advises Appian Capital Advisory on the acquisition of the Omitiomire copper project in Namibia
Herbert Smith Freehills Kramer has advised Appian Capital Advisory Limited (“Appian”), a leading investment adviser focused on the mining sector, on its …
5 มิถุนายน 2026
Herbert Smith Freehills Kramer assists Ampol to secure ACCC clearance for its A$1.1 billion acquisition of EG Australia – the first Phase II clearance under Australia’s new merger regime
HSF Kramer has advised Ampol Limited on securing ACCC clearance for its proposed $1.1 billion acquisition of EG Australia. The ACCC approved Ampol’s …